Autism Spectrum Disorder Therapeutics Market to Grow at a CAGR of 6.5% Over the Forecast Period; Introduction of Drugs Focused on ASD Symptoms to Propel the Market Expansion

The global autism spectrum disorder therapeutics market size was valued at USD 2.11 billion in 2024. The market is projected to grow from USD 2.21 billion in 2025 to USD 3.44 billion by 2032, exhibiting a CAGR of 6.5% during the forecast period.       

Fortune Business Insights™ presents this information in its report titled, “Autism Spectrum Disorder Therapeutics Market Size, Share & Industry Analysis, By Drug Type (Antipsychotic Drugs, Selective Serotonin Reuptake Inhibitors, Stimulants, Sleep Medications, and Others), By Disease (Autistic Disorder, Asperger Syndrome, Pervasive Developmental Disorder, and Others), By Age Group (Pediatrics and Adults), By Distribution Channel (Hospital Pharmacies, Drugs Stores & Retail Pharmacies, and Online Pharmacies) and Regional Forecast, 2025-2032”. 

Autism spectrum disorder (ASD) is a combination of neurological disorders that are described by persistent lack in social interaction/ communication and a repetitive or restricted behavioural or activities pattern. The three major types of disorders affecting the global population include Asperger’s syndrome, Autistic disorder and Pervasive Development Disorder (PDD). The market is noticing a significant growth owing to the increase in prevalence of ASD, favourable government initiatives and rising awareness among the general population. Few prominent players operating in the market include H. Lundbeck A/S, Johnson & Johnson Services Inc., and Otsuka Pharmaceutical Co., Ltd.

Acceptance of Innovative Products Manufactured by Otsuka Pharmaceutical and Lundbeck A/S to Fuel Market Development

In September 2022, Otsuka Pharmaceutical Co., Ltd., and H. Lundbeck A/S acknowledged an acceptance of their New Drug Application (NDA) for aripiprazole, a medicine specified for the treatment of schizophrenia in adults. 

Government Focus to Escalate Awareness Regarding ASD Augments the Market Growth

Increasing number of government policies concerned with the awareness of autism spectrum disorder (ASD) in different countries tend to propel the autism spectrum disorder market growth. Initiatives such as creating different foundations and allocating funding for the awareness about ASD among the population. Additionally, regulatory bodies creating awareness about the treatments and therapies present for ASD is also leading to early diagnosis of the symptoms and treatment via therapies and medication.

For instance, in May 2025, Brazil’s Ministry of Sports presented an autism-focused sports program at the 17th Conference of States Parties to the Convention on the Rights of Persons with Disabilities. This initiative focused on promoting the social presence of individuals suffering from autism spectrum disorder (ASD) through sports.

Conversely, the presence of complementary and alternative therapies for autism is hindering market growth.

Ongoing R&D Initiatives to Increase Key Player’s Market Dominance

Strong distribution network globally, higher focus on R&D initiatives, and presence of permitted products are few factors supporting the dominance of major companies in the market. These players concentrate on the manufacturing of generic forms of drugs to treat the condition.

Notable Industry Development:

• February 2025: DeFloria, Inc. stated that the U.S. Food and Drug Administration (FDA) had permitted its Investigational New Drug (IND) application, consenting the company to move forward with a Phase 2 clinical trial of AJA001, an orally administered cannabinoid therapy.

List of the Companies Profiled in the Report

• Curemark, LLC (U.S.)
• Yamo Pharmaceuticals (U.S.)
• Pfizer Inc.  (U.S.)
• Eli Lilly and Company (U.S.)
• AstraZeneca (UK)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Otsuka Holdings Co. Ltd. (Japan)
• Johnson & Johnson Services, Inc. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• H. Lundbeck A/S (Denmark)

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/industry-reports/autism-spectrum-disorder-therapeutics-market-101207

Further Report Findings

• North America held the highest autism spectrum disorder market share, attributed to the growing number of autism cases, rising adoption of drugs, and increasing support from government authorities.
• Market growth in Europe is driven by increasing awareness and screening, wide diagnostic criteria and access to aid.
• Market expansion in Asia Pacific is propelled by increased demand for effective treatment across Asian countries.
• In terms of disease, the autistic disorder segment led the market in 2024, as there is increasing concern about the cumulating autistic people.

Table of Segmentation